Coffee and tea consumption, genotype-based CYP1A2 and NAT2 activity and colorectal cancer risk - Results from the EPIC cohort study

Vincent K. Dik, H. B. Bueno-De-Mesquita, Martijn G H Van Oijen, Peter D. Siersema, Cuno S P M Uiterwaal, Carla H. Van Gils, Fränzel J B Van Duijnhoven, Stéphane Cauchi, Loic Yengo, Philippe Froguel, Kim Overvad, Bodil H. Bech, Anne Tjønneland, Anja Olsen, Marie Christine Boutron-Ruault, Antoine Racine, Guy Fagherazzi, Tilman Kühn, Daniele Campa, Heiner BoeingKrasimira Aleksandrova, Antonia Trichopoulou, Eleni Peppa, Eleni Oikonomou, Domenico Palli, Sara Grioni, Paolo Vineis, Rosaria Tumino, Salvatore Panico, Petra H M Peeters, Elisabete Weiderpass, Dagrun Engeset, Tonje Braaten, Miren Dorronsoro, María Dolores Chirlaque, María José Sánchez, Aurelio Barricarte, Raul Zamora-Ros, Marcial Argüelles, Karin Jirström, Peter Wallström, Lena M. Nilsson, Ingrid Ljuslinder, Ruth C. Travis, Kay Tee Khaw, Nick Wareham, Heinz Freisling, Idlir Licaj, Mazda Jenab, Marc J. Gunter, Neil Murphy, Dora Romaguera-Bosch, Elio Riboli

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Coffee and tea contain numerous antimutagenic and antioxidant components and high levels of caffeine that may protect against colorectal cancer (CRC). We investigated the association between coffee and tea consumption and CRC risk and studied potential effect modification by CYP1A2 and NAT2 genotypes, enzymes involved in the metabolization of caffeine. Data from 477,071 participants (70.2% female) of the European Investigation into Cancer and Nutrition (EPIC) cohort study were analyzed. At baseline (1992-2000) habitual (total, caffeinated and decaffeinated) coffee and tea consumption was assessed with dietary questionnaires. Cox proportional hazards models were used to estimate adjusted hazard ratio's (HR) and 95% confidence intervals (95% CI). Potential effect modification by genotype-based CYP1A2 and NAT2 activity was studied in a nested case-control set of 1,252 cases and 2,175 controls. After a median follow-up of 11.6 years, 4,234 participants developed CRC (mean age 64.7-±-8.3 years). Total coffee consumption (high vs. non/low) was not associated with CRC risk (HR 1.06, 95% CI 0.95-1.18) or subsite cancers, and no significant associations were found for caffeinated (HR 1.10, 95% CI 0.97-1.26) and decaffeinated coffee (HR 0.96, 95% CI 0.84-1.11) and tea (HR 0.97, 95% CI 0.86-1.09). High coffee and tea consuming subjects with slow CYP1A2 or NAT2 activity had a similar CRC risk compared to non/low coffee and tea consuming subjects with a fast CYP1A2 or NAT2 activity, which suggests that caffeine metabolism does not affect the link between coffee and tea consumption and CRC risk. This study shows that coffee and tea consumption is not likely to be associated with overall CRC. What's new? Coffee and tea contain numerous compounds that may protect against colorectal cancer (CRC). In this study of more than 475,000 participants over more than a decade, the authors investigated whether coffee or tea consumption is associated with an altered risk of developing CRC. They also asked whether genetic variations in two enzymes involved in caffeine metabolism (CYP1A2 and NAT2) might affect this risk. They conclude that neither consumption patterns, nor genetic differences in caffeine metabolism, appear to have a significant impact on CRC risk.

Original languageEnglish
Pages (from-to)401-412
Number of pages12
JournalInternational Journal of Cancer
Volume135
Issue number2
DOIs
Publication statusPublished - Jul 15 2014

Fingerprint

Cytochrome P-450 CYP1A2
Coffee
Tea
Colorectal Neoplasms
Cohort Studies
Genotype
Caffeine
Confidence Intervals
Enzymes
Proportional Hazards Models
Neoplasms
Antioxidants
Odds Ratio

Keywords

  • coffee
  • Colorectal cancer
  • CYP1A2
  • NAT2
  • tea

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dik, V. K., Bueno-De-Mesquita, H. B., Van Oijen, M. G. H., Siersema, P. D., Uiterwaal, C. S. P. M., Van Gils, C. H., ... Riboli, E. (2014). Coffee and tea consumption, genotype-based CYP1A2 and NAT2 activity and colorectal cancer risk - Results from the EPIC cohort study. International Journal of Cancer, 135(2), 401-412. https://doi.org/10.1002/ijc.28655

Coffee and tea consumption, genotype-based CYP1A2 and NAT2 activity and colorectal cancer risk - Results from the EPIC cohort study. / Dik, Vincent K.; Bueno-De-Mesquita, H. B.; Van Oijen, Martijn G H; Siersema, Peter D.; Uiterwaal, Cuno S P M; Van Gils, Carla H.; Van Duijnhoven, Fränzel J B; Cauchi, Stéphane; Yengo, Loic; Froguel, Philippe; Overvad, Kim; Bech, Bodil H.; Tjønneland, Anne; Olsen, Anja; Boutron-Ruault, Marie Christine; Racine, Antoine; Fagherazzi, Guy; Kühn, Tilman; Campa, Daniele; Boeing, Heiner; Aleksandrova, Krasimira; Trichopoulou, Antonia; Peppa, Eleni; Oikonomou, Eleni; Palli, Domenico; Grioni, Sara; Vineis, Paolo; Tumino, Rosaria; Panico, Salvatore; Peeters, Petra H M; Weiderpass, Elisabete; Engeset, Dagrun; Braaten, Tonje; Dorronsoro, Miren; Chirlaque, María Dolores; Sánchez, María José; Barricarte, Aurelio; Zamora-Ros, Raul; Argüelles, Marcial; Jirström, Karin; Wallström, Peter; Nilsson, Lena M.; Ljuslinder, Ingrid; Travis, Ruth C.; Khaw, Kay Tee; Wareham, Nick; Freisling, Heinz; Licaj, Idlir; Jenab, Mazda; Gunter, Marc J.; Murphy, Neil; Romaguera-Bosch, Dora; Riboli, Elio.

In: International Journal of Cancer, Vol. 135, No. 2, 15.07.2014, p. 401-412.

Research output: Contribution to journalArticle

Dik, VK, Bueno-De-Mesquita, HB, Van Oijen, MGH, Siersema, PD, Uiterwaal, CSPM, Van Gils, CH, Van Duijnhoven, FJB, Cauchi, S, Yengo, L, Froguel, P, Overvad, K, Bech, BH, Tjønneland, A, Olsen, A, Boutron-Ruault, MC, Racine, A, Fagherazzi, G, Kühn, T, Campa, D, Boeing, H, Aleksandrova, K, Trichopoulou, A, Peppa, E, Oikonomou, E, Palli, D, Grioni, S, Vineis, P, Tumino, R, Panico, S, Peeters, PHM, Weiderpass, E, Engeset, D, Braaten, T, Dorronsoro, M, Chirlaque, MD, Sánchez, MJ, Barricarte, A, Zamora-Ros, R, Argüelles, M, Jirström, K, Wallström, P, Nilsson, LM, Ljuslinder, I, Travis, RC, Khaw, KT, Wareham, N, Freisling, H, Licaj, I, Jenab, M, Gunter, MJ, Murphy, N, Romaguera-Bosch, D & Riboli, E 2014, 'Coffee and tea consumption, genotype-based CYP1A2 and NAT2 activity and colorectal cancer risk - Results from the EPIC cohort study', International Journal of Cancer, vol. 135, no. 2, pp. 401-412. https://doi.org/10.1002/ijc.28655
Dik, Vincent K. ; Bueno-De-Mesquita, H. B. ; Van Oijen, Martijn G H ; Siersema, Peter D. ; Uiterwaal, Cuno S P M ; Van Gils, Carla H. ; Van Duijnhoven, Fränzel J B ; Cauchi, Stéphane ; Yengo, Loic ; Froguel, Philippe ; Overvad, Kim ; Bech, Bodil H. ; Tjønneland, Anne ; Olsen, Anja ; Boutron-Ruault, Marie Christine ; Racine, Antoine ; Fagherazzi, Guy ; Kühn, Tilman ; Campa, Daniele ; Boeing, Heiner ; Aleksandrova, Krasimira ; Trichopoulou, Antonia ; Peppa, Eleni ; Oikonomou, Eleni ; Palli, Domenico ; Grioni, Sara ; Vineis, Paolo ; Tumino, Rosaria ; Panico, Salvatore ; Peeters, Petra H M ; Weiderpass, Elisabete ; Engeset, Dagrun ; Braaten, Tonje ; Dorronsoro, Miren ; Chirlaque, María Dolores ; Sánchez, María José ; Barricarte, Aurelio ; Zamora-Ros, Raul ; Argüelles, Marcial ; Jirström, Karin ; Wallström, Peter ; Nilsson, Lena M. ; Ljuslinder, Ingrid ; Travis, Ruth C. ; Khaw, Kay Tee ; Wareham, Nick ; Freisling, Heinz ; Licaj, Idlir ; Jenab, Mazda ; Gunter, Marc J. ; Murphy, Neil ; Romaguera-Bosch, Dora ; Riboli, Elio. / Coffee and tea consumption, genotype-based CYP1A2 and NAT2 activity and colorectal cancer risk - Results from the EPIC cohort study. In: International Journal of Cancer. 2014 ; Vol. 135, No. 2. pp. 401-412.
@article{18a2848f19b74b4992e1c6d49b7c92f0,
title = "Coffee and tea consumption, genotype-based CYP1A2 and NAT2 activity and colorectal cancer risk - Results from the EPIC cohort study",
abstract = "Coffee and tea contain numerous antimutagenic and antioxidant components and high levels of caffeine that may protect against colorectal cancer (CRC). We investigated the association between coffee and tea consumption and CRC risk and studied potential effect modification by CYP1A2 and NAT2 genotypes, enzymes involved in the metabolization of caffeine. Data from 477,071 participants (70.2{\%} female) of the European Investigation into Cancer and Nutrition (EPIC) cohort study were analyzed. At baseline (1992-2000) habitual (total, caffeinated and decaffeinated) coffee and tea consumption was assessed with dietary questionnaires. Cox proportional hazards models were used to estimate adjusted hazard ratio's (HR) and 95{\%} confidence intervals (95{\%} CI). Potential effect modification by genotype-based CYP1A2 and NAT2 activity was studied in a nested case-control set of 1,252 cases and 2,175 controls. After a median follow-up of 11.6 years, 4,234 participants developed CRC (mean age 64.7-±-8.3 years). Total coffee consumption (high vs. non/low) was not associated with CRC risk (HR 1.06, 95{\%} CI 0.95-1.18) or subsite cancers, and no significant associations were found for caffeinated (HR 1.10, 95{\%} CI 0.97-1.26) and decaffeinated coffee (HR 0.96, 95{\%} CI 0.84-1.11) and tea (HR 0.97, 95{\%} CI 0.86-1.09). High coffee and tea consuming subjects with slow CYP1A2 or NAT2 activity had a similar CRC risk compared to non/low coffee and tea consuming subjects with a fast CYP1A2 or NAT2 activity, which suggests that caffeine metabolism does not affect the link between coffee and tea consumption and CRC risk. This study shows that coffee and tea consumption is not likely to be associated with overall CRC. What's new? Coffee and tea contain numerous compounds that may protect against colorectal cancer (CRC). In this study of more than 475,000 participants over more than a decade, the authors investigated whether coffee or tea consumption is associated with an altered risk of developing CRC. They also asked whether genetic variations in two enzymes involved in caffeine metabolism (CYP1A2 and NAT2) might affect this risk. They conclude that neither consumption patterns, nor genetic differences in caffeine metabolism, appear to have a significant impact on CRC risk.",
keywords = "coffee, Colorectal cancer, CYP1A2, NAT2, tea",
author = "Dik, {Vincent K.} and Bueno-De-Mesquita, {H. B.} and {Van Oijen}, {Martijn G H} and Siersema, {Peter D.} and Uiterwaal, {Cuno S P M} and {Van Gils}, {Carla H.} and {Van Duijnhoven}, {Fr{\"a}nzel J B} and St{\'e}phane Cauchi and Loic Yengo and Philippe Froguel and Kim Overvad and Bech, {Bodil H.} and Anne Tj{\o}nneland and Anja Olsen and Boutron-Ruault, {Marie Christine} and Antoine Racine and Guy Fagherazzi and Tilman K{\"u}hn and Daniele Campa and Heiner Boeing and Krasimira Aleksandrova and Antonia Trichopoulou and Eleni Peppa and Eleni Oikonomou and Domenico Palli and Sara Grioni and Paolo Vineis and Rosaria Tumino and Salvatore Panico and Peeters, {Petra H M} and Elisabete Weiderpass and Dagrun Engeset and Tonje Braaten and Miren Dorronsoro and Chirlaque, {Mar{\'i}a Dolores} and S{\'a}nchez, {Mar{\'i}a Jos{\'e}} and Aurelio Barricarte and Raul Zamora-Ros and Marcial Arg{\"u}elles and Karin Jirstr{\"o}m and Peter Wallstr{\"o}m and Nilsson, {Lena M.} and Ingrid Ljuslinder and Travis, {Ruth C.} and Khaw, {Kay Tee} and Nick Wareham and Heinz Freisling and Idlir Licaj and Mazda Jenab and Gunter, {Marc J.} and Neil Murphy and Dora Romaguera-Bosch and Elio Riboli",
year = "2014",
month = "7",
day = "15",
doi = "10.1002/ijc.28655",
language = "English",
volume = "135",
pages = "401--412",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Coffee and tea consumption, genotype-based CYP1A2 and NAT2 activity and colorectal cancer risk - Results from the EPIC cohort study

AU - Dik, Vincent K.

AU - Bueno-De-Mesquita, H. B.

AU - Van Oijen, Martijn G H

AU - Siersema, Peter D.

AU - Uiterwaal, Cuno S P M

AU - Van Gils, Carla H.

AU - Van Duijnhoven, Fränzel J B

AU - Cauchi, Stéphane

AU - Yengo, Loic

AU - Froguel, Philippe

AU - Overvad, Kim

AU - Bech, Bodil H.

AU - Tjønneland, Anne

AU - Olsen, Anja

AU - Boutron-Ruault, Marie Christine

AU - Racine, Antoine

AU - Fagherazzi, Guy

AU - Kühn, Tilman

AU - Campa, Daniele

AU - Boeing, Heiner

AU - Aleksandrova, Krasimira

AU - Trichopoulou, Antonia

AU - Peppa, Eleni

AU - Oikonomou, Eleni

AU - Palli, Domenico

AU - Grioni, Sara

AU - Vineis, Paolo

AU - Tumino, Rosaria

AU - Panico, Salvatore

AU - Peeters, Petra H M

AU - Weiderpass, Elisabete

AU - Engeset, Dagrun

AU - Braaten, Tonje

AU - Dorronsoro, Miren

AU - Chirlaque, María Dolores

AU - Sánchez, María José

AU - Barricarte, Aurelio

AU - Zamora-Ros, Raul

AU - Argüelles, Marcial

AU - Jirström, Karin

AU - Wallström, Peter

AU - Nilsson, Lena M.

AU - Ljuslinder, Ingrid

AU - Travis, Ruth C.

AU - Khaw, Kay Tee

AU - Wareham, Nick

AU - Freisling, Heinz

AU - Licaj, Idlir

AU - Jenab, Mazda

AU - Gunter, Marc J.

AU - Murphy, Neil

AU - Romaguera-Bosch, Dora

AU - Riboli, Elio

PY - 2014/7/15

Y1 - 2014/7/15

N2 - Coffee and tea contain numerous antimutagenic and antioxidant components and high levels of caffeine that may protect against colorectal cancer (CRC). We investigated the association between coffee and tea consumption and CRC risk and studied potential effect modification by CYP1A2 and NAT2 genotypes, enzymes involved in the metabolization of caffeine. Data from 477,071 participants (70.2% female) of the European Investigation into Cancer and Nutrition (EPIC) cohort study were analyzed. At baseline (1992-2000) habitual (total, caffeinated and decaffeinated) coffee and tea consumption was assessed with dietary questionnaires. Cox proportional hazards models were used to estimate adjusted hazard ratio's (HR) and 95% confidence intervals (95% CI). Potential effect modification by genotype-based CYP1A2 and NAT2 activity was studied in a nested case-control set of 1,252 cases and 2,175 controls. After a median follow-up of 11.6 years, 4,234 participants developed CRC (mean age 64.7-±-8.3 years). Total coffee consumption (high vs. non/low) was not associated with CRC risk (HR 1.06, 95% CI 0.95-1.18) or subsite cancers, and no significant associations were found for caffeinated (HR 1.10, 95% CI 0.97-1.26) and decaffeinated coffee (HR 0.96, 95% CI 0.84-1.11) and tea (HR 0.97, 95% CI 0.86-1.09). High coffee and tea consuming subjects with slow CYP1A2 or NAT2 activity had a similar CRC risk compared to non/low coffee and tea consuming subjects with a fast CYP1A2 or NAT2 activity, which suggests that caffeine metabolism does not affect the link between coffee and tea consumption and CRC risk. This study shows that coffee and tea consumption is not likely to be associated with overall CRC. What's new? Coffee and tea contain numerous compounds that may protect against colorectal cancer (CRC). In this study of more than 475,000 participants over more than a decade, the authors investigated whether coffee or tea consumption is associated with an altered risk of developing CRC. They also asked whether genetic variations in two enzymes involved in caffeine metabolism (CYP1A2 and NAT2) might affect this risk. They conclude that neither consumption patterns, nor genetic differences in caffeine metabolism, appear to have a significant impact on CRC risk.

AB - Coffee and tea contain numerous antimutagenic and antioxidant components and high levels of caffeine that may protect against colorectal cancer (CRC). We investigated the association between coffee and tea consumption and CRC risk and studied potential effect modification by CYP1A2 and NAT2 genotypes, enzymes involved in the metabolization of caffeine. Data from 477,071 participants (70.2% female) of the European Investigation into Cancer and Nutrition (EPIC) cohort study were analyzed. At baseline (1992-2000) habitual (total, caffeinated and decaffeinated) coffee and tea consumption was assessed with dietary questionnaires. Cox proportional hazards models were used to estimate adjusted hazard ratio's (HR) and 95% confidence intervals (95% CI). Potential effect modification by genotype-based CYP1A2 and NAT2 activity was studied in a nested case-control set of 1,252 cases and 2,175 controls. After a median follow-up of 11.6 years, 4,234 participants developed CRC (mean age 64.7-±-8.3 years). Total coffee consumption (high vs. non/low) was not associated with CRC risk (HR 1.06, 95% CI 0.95-1.18) or subsite cancers, and no significant associations were found for caffeinated (HR 1.10, 95% CI 0.97-1.26) and decaffeinated coffee (HR 0.96, 95% CI 0.84-1.11) and tea (HR 0.97, 95% CI 0.86-1.09). High coffee and tea consuming subjects with slow CYP1A2 or NAT2 activity had a similar CRC risk compared to non/low coffee and tea consuming subjects with a fast CYP1A2 or NAT2 activity, which suggests that caffeine metabolism does not affect the link between coffee and tea consumption and CRC risk. This study shows that coffee and tea consumption is not likely to be associated with overall CRC. What's new? Coffee and tea contain numerous compounds that may protect against colorectal cancer (CRC). In this study of more than 475,000 participants over more than a decade, the authors investigated whether coffee or tea consumption is associated with an altered risk of developing CRC. They also asked whether genetic variations in two enzymes involved in caffeine metabolism (CYP1A2 and NAT2) might affect this risk. They conclude that neither consumption patterns, nor genetic differences in caffeine metabolism, appear to have a significant impact on CRC risk.

KW - coffee

KW - Colorectal cancer

KW - CYP1A2

KW - NAT2

KW - tea

UR - http://www.scopus.com/inward/record.url?scp=84900036010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900036010&partnerID=8YFLogxK

U2 - 10.1002/ijc.28655

DO - 10.1002/ijc.28655

M3 - Article

C2 - 24318358

AN - SCOPUS:84900036010

VL - 135

SP - 401

EP - 412

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -